Your browser is no longer supported. Please, upgrade your browser.
Omeros Corporation
Index- P/E- EPS (ttm)-2.38 Insider Own4.41% Shs Outstand58.23M Perf Week9.34%
Market Cap1.21B Forward P/E- EPS next Y-1.89 Insider Trans-0.53% Shs Float53.76M Perf Month32.91%
Income-130.00M PEG- EPS next Q-0.65 Inst Own57.40% Short Float23.25% Perf Quarter76.41%
Sales96.60M P/S12.50 EPS this Y34.60% Inst Trans0.06% Short Ratio14.44 Perf Half Y38.91%
Book/sh-1.50 P/B- EPS next Y24.40% ROA-94.10% Target Price- Perf Year43.58%
Cash/sh2.50 P/C7.87 EPS next 5Y- ROE106.20% 52W Range8.50 - 25.46 Perf YTD37.70%
Dividend- P/FCF- EPS past 5Y5.10% ROI-121.90% 52W High-22.74% Beta1.51
Dividend %- Quick Ratio4.10 Sales past 5Y190.70% Gross Margin98.70% 52W Low131.41% ATR0.95
Employees258 Current Ratio4.10 Sales Q/Q-12.70% Oper. Margin- RSI (14)79.32 Volatility7.23% 4.92%
OptionableYes Debt/Eq- EPS Q/Q-98.10% Profit Margin- Rel Volume0.96 Prev Close18.62
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume865.49K Price19.67
Recom2.20 SMA2022.61% SMA5038.78% SMA20044.97% Volume832,306 Change5.64%
Oct-20-20Initiated BofA Securities Buy $21
Aug-21-20Reiterated H.C. Wainwright Buy $34 → $32
Aug-14-20Reiterated Maxim Group Buy $25 → $20
May-06-19Initiated Cantor Fitzgerald Overweight $26
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Mar-02-16Reiterated Needham Buy $30 → $28
Feb-29-16Reiterated Wedbush Outperform $65 → $62
Nov-11-15Reiterated Needham Buy $32 → $30
Aug-18-15Reiterated WBB Securities Strong Buy $60 → $75
Aug-10-15Initiated ROTH Capital Buy $38
Jan-19-21 08:30AM  
Jan-11-21 04:30PM  
Dec-15-20 11:42PM  
Dec-05-20 02:43AM  
Dec-03-20 07:30AM  
Dec-02-20 08:57AM  
Nov-18-20 09:00AM  
Nov-12-20 09:54AM  
Nov-09-20 05:45PM  
Nov-05-20 07:00AM  
Nov-03-20 12:31PM  
Oct-28-20 09:00AM  
Oct-22-20 08:00AM  
Oct-20-20 09:56AM  
Oct-16-20 08:30AM  
Oct-15-20 08:00AM  
Oct-01-20 09:00AM  
Sep-14-20 02:10PM  
Sep-11-20 07:00AM  
Sep-09-20 08:45AM  
Sep-03-20 09:38AM  
Aug-31-20 08:18AM  
Aug-12-20 12:35PM  
Aug-11-20 08:20AM  
Aug-10-20 05:45PM  
Aug-06-20 12:30PM  
Jul-26-20 06:27AM  
Jul-15-20 03:06PM  
Jun-24-20 04:27PM  
Jun-12-20 08:30AM  
Jun-11-20 08:45AM  
Jun-08-20 02:28PM  
May-26-20 06:45PM  
May-14-20 09:00AM  
May-12-20 06:01AM  
May-11-20 06:55PM  
May-08-20 08:36AM  
May-05-20 07:00AM  
Mar-11-20 03:38PM  
Mar-04-20 10:00AM  
Mar-02-20 05:35PM  
Feb-24-20 07:00AM  
Feb-11-20 09:35AM  
Feb-03-20 03:49PM  
Jan-23-20 05:30PM  
Dec-20-19 05:16PM  
Dec-18-19 08:30AM  
Dec-16-19 08:30AM  
Dec-13-19 09:30AM  
Dec-10-19 08:30AM  
Dec-05-19 07:14AM  
Dec-04-19 04:11PM  
Dec-03-19 11:45PM  
Nov-20-19 08:45AM  
Nov-19-19 08:45AM  
Nov-16-19 08:10AM  
Nov-13-19 02:00PM  
Nov-12-19 05:35PM  
Nov-11-19 05:16PM  
Nov-08-19 08:30AM  
Nov-07-19 05:45PM  
Nov-06-19 08:15AM  
Nov-04-19 03:00PM  
Nov-01-19 11:22AM  
Oct-29-19 09:00AM  
Oct-28-19 08:45AM  
Oct-21-19 09:46AM  
Oct-18-19 04:31AM  
Oct-01-19 08:30AM  
Sep-25-19 09:01PM  
Sep-16-19 08:45AM  
Sep-11-19 08:45AM  
Sep-10-19 10:01AM  
Sep-06-19 07:00AM  
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JACOBSEN MICHAEL AVP FINANCE AND CAOJan 20Option Exercise9.3710,00093,70014,000Jan 21 05:15 PM
JACOBSEN MICHAEL AVP FINANCE AND CAOJan 19Sale19.959,500189,5254,000Jan 21 05:15 PM
Cable Thomas J.DirectorJan 13Option Exercise4.535,00022,65040,067Jan 15 05:15 PM
Cable Thomas J.DirectorJan 13Sale16.975,00084,85035,067Jan 15 05:15 PM
Cable Thomas J.DirectorMay 13Option Exercise5.925,00029,60040,067May 15 08:00 PM
Cable Thomas J.DirectorMay 13Sale14.405,00071,99935,067May 15 08:00 PM
Hood Leroy E. MD PhDDirectorMar 13Option Exercise5.925,00029,60069,390Mar 17 05:25 PM